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The left ventricle (LV) undergoes hypertrophic remodeling in response to chronic PO, a condition initiated by arterial hypertension or aortic stenosis that frequently leads to the development of chronic heart failure 1 . Although the mechanisms by which PO leads to hypertrophic remodeling have not been completely defined, changes in miRNA expression makes an important contribution 2, 3 . In particular, miR-133a is abundantly expressed in the heart and plays a critical role in hypertrophy; miR-133a is downregulated in the LV and atria in multiple murine models of cardiac hypertrophy 4, 5 , in dilated atria from patients with mitral stenosis, and in ventricles from young patients suffering from hypertrophic cardiomyopathy 4 .
In PO-induced remodeling, the myocardium is subjected to important modifications of the extracellular matrix (ECM) resulting in myocardial fibrosis. Key proteins in this process are serum response factor (SRF), connective tissue growth factor (CTGF) and collagen type 1 (COL1a1), all of which are post-transcriptionally regulated by miR-133a [6] [7] [8] [9] . Thus, when miR133a is downregulated during cardiac hypertrophy and LV dilation, these pro-hypertrophic and pro-fibrotic factors are upregulated and contribute to the progression to heart failure.
Little is known about what regulates the PO-induced downregulation of miR-133a. Here we examine whether epigenetic regulators may play a role in miR-133a expression in PO hypertrophy. Histone acetyltransferases (HATs) and HDACs are the enzymes that carry out the addition and the removal respectively of the acetyl moiety on lysine residues of histone proteins 10 . HDAC inhibition reduced fibrosis in PO hypertrophy and blocked COL1a1 upregulation 11 .
In addition, HDAC inhibitor treatment of rat neonatal cardiomyocytes upregulated miR-133a expression 5 . Therefore, we hypothesize that HDACs regulate miR-133a expression during PO hypertrophy and that Class I and IIb HDAC inhibition could attenuate pathological cardiac remodeling and improve cardiac function.
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Methods
Transverse Aortic Constriction (TAC)
The methods used to create TAC-induced PO hypertrophy have been described previously 12 . All CD1 mice were between 11 and 17 wk of age at the time of TAC. Suberoylanilide hydroxamic acid (SAHA also known as Vorinostat, cat# S1047, Selleck, Houston, TX) was dissolved in 5 M 2-hydroxypropyl--cyclodextrin, in the drinking water (75 mg/kg/day) 13 . Mice were studied 2 weeks (n= 34 
HDAC Activity Assay
HDAC activity was measured with the homogenous fluorescence release HDAC deacetylase assay as previously described 14 . AMC fluorescence was measured using Fluoroskan Ascent from Labsystems at excitation 355/emission 460 and background signals from pre-developed blanks were subtracted. The data were standardized using control, and the absolute deacetylated substrates were calculated based on the standard curve generated by non-acetylated AMC-KGL substrate under the same conditions. mice, 10 received SAHA drug for 2 weeks). Vehicle water consisted of 5M 2-hyd yd dro o oxy xy xypr pr prop op opyl yl yl--cyclod od odex ex extr tr trin in in, , alon on one. e All procedures performed w wer er ere e e approved by the Inst st stit it itut u ion Animal Care and U U Use e e Committe t e e e of of of the he he M M Med ed edic i i al al al U U Uni ni nive ve vers rs rsit it ity of of of S S South h h C Car ar rol ol olin in ina a a in i i a a acc cc c or or orda da dan n nce e e wi wi with th th N N Nat at atio io i na na nal l l n n nst st s it it itut u es of f He H H a a alth h h gu u uid d deline e es. 
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RNA Isolation
Left ventricular myocardial tissue (30 to 50 mg) was place in RNAlater and then homogenized in QIAzol Lysis Reagent and total RNA (including miRNA and small RNA molecules) was purified with the miRNeasy Mini Kit (cat# 217004, Qiagen, Valencia, CA). Total and small RNA concentration was determined with "Agilent RNA 6000 Nano Kit" on the Agilent
Bioanalyzer 2100 (Agilent, Santa Clara, CA).
microRNA Quantification
Using the Taqman microRNA Reverse Transcription Kit and Taqman microRNA Assays (Life Technologies), isolated RNA (10 ng) was reverse transcribed and expression level of mature miR-133a (assay ID: 002246, miR-133a-1 and miR-133a-2 combined) was determined using a CFX96 Real Time System/ C1000 thermal cycler (Biorad, Hercules, CA). The relative expression of miR-133a was calculated and normalized to the small nuclear RNA RNU6B (NC_000010.11, assay ID: 001093) using the comparative cycle threshold (CT) method 15 . Relative expression intensity values were calculated as 2 -normalized to the referent control RNU6B.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as previously described 16 with some modifications. 50 mg of heart tissue from specimen in each group was minced in cold PBS with PMSF, homogenized and cross-linked with formaldehyde (10 minutes). Cross-linking activity was quenched with the addition of glycine for 5 minutes then suspended in SDS lysis buffer and incubated on ice for 30 min. The cell lysates were sonicated for 6 cycles (10 seconds "on" 10 seconds "off"), and the cell Technologies), isolated RNA (10 ng) was reverse transcribed and expression lev ve e el o o of ma ma matu tu ture re re miR-1 133 33a a (a (a ( ss s ay y y I ID: 002246, miR-133a-1 and miR-R 133a-2 combined) w w was a a determined using a C C CFX X X96 Real T Tim im ime e e Sy Sy yst st stem em em/ / / C1 C1 100 00 000 0 0 th th ther er erma m m l cy cy cyc c cler (B (Bior rad ad ad, He He Herc cul ul ules es s, , , CA CA A) ). ). The e e re re rela la lati ti tive ve e ex ex xpr r res e sion of mi mi iR R R-133a 3a 3a was s ca al a cula a ate te t d d d a a and no no norma a alized d d t t to o o th h he e e sm m mal ll l nucl l lea a ar RN RN RNA RN RN NU6 U6 U6B B B NC_000010.11, assay ID: 00109 9 93 3 3) ) ) us u ing g g the e e co o omp mp mpar r rat at ativ iv i e cy y ycle threshold (CT) method 5 . . Re Rela lati tive ve e exp xp pre ress ssio ion n in inte tens nsit ity y y va valu lues es w wer ere e ca calc lcul ulat ated ed a as (cat# sc7872), HDAC2 (cat# sc7899X), HDAC3 (cat# sc11417), SRF (cat# 13029). The proximal promoter for enhancer regions miR-133a1 and miR-133a2 were PCR amplified from the immunoprecipitated and non-immunoprecipitated (input control) chromatin using sense and antisense primers 17 ( Supplemental Table) . Primers that amplified regions distal to the proximal promoter were also used as negative PCR controls.
Immunoblotting
LV myocardial samples were homogenized in lysis buffer and supernatant and pellet fractions for each sample run on SDS-PAGE and Western blotting was performed using CTGF antibody
(1:2500, Abcam, cat# ab6992), acetylated histone H3 (Cell Signaling #9649), histone H3
(Millipore 06-755), acetylated -Tubulin (Santa Cruz 23950) and -Tubulin (Sigma, T9026).
Band intensity was quantified using ImageJ 1.47t software (NIH, USA, http://imagej.nih.gov/ij/).
Protein samples (5 g) from DCM cells (siRNA experiment) were run on 4-12% bis-tris gel and Western blotting was performed using HDAC2 antibody (Santa Cruz, cat# sc7899) and GAPDH (Fitzgerald Industries International, cat# 10R-G109a).
promoter were also used as negative PCR controls.
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Echocardiography
Echocardiographic measurements were made using a 40 MHz mechanical scanning transducer (707B) and a Vevo 770 echocardiograph (VisualSonics, Toronto, Canada) as previously described 18 . LV weight (LVW), LV end-diastolic volume (LV EDV), LV ejection fraction (LV EF), body weight (BW), tibia length (TL) and left atrial (LA) diameter were measured using the American Society of Echocardiography criteria 19 . LV mass was normalized to body weight. The LA diameter was used to reflect chronic changes in LV diastolic pressure; diameter increases as a function of sustained increased pressure (i.e., an integration of pressure over time) 20, 21 .
Papillary Muscle Preparation and Passive Stiffness Measurements
Passive myocardium stiffness was assessed using isolated papillary muscles as previously described 12, [22] [23] [24] [25] .
Collagen Content by Light Microscopy
The collagen content of the LV myocardium was determined by light microscopy as previously described 12 . Briefly, LV sections were stained with picrosirius red (PSR) to detect collagen fibers and were viewed with polarized light under dark field optics to detect birefringence of collagen fibers. Quantitative analysis of PSR-stained images captured with polarized light was performed. Five fields chosen at random from each mouse were scanned with SigmaScan software. Fields with large blood vessels were excluded from the analysis. Areas examined were distributed throughout the myocardium from the subendocardium to the subepicardium and excluded the epicardial surface. Collagen volume fraction was calculated as the area stained by PSR divided by the total area of interest.
Papillary Muscle Preparation and Passive Stiffness Measurements
Passiv ve e my my yoc cardi di dium u stiffness was assessed using g is isol o ated papillary mus scl cl cles as previously de de desc c cribed 12, 2 2 22-25 .
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Myocardial Fibroblasts Cultures
Primary cultures of myocardial fibroblasts were established from LV myocardial biopsies (2 x 2 mm) from patients (n = 5) with end-stage non-ischemic dilated cardiomyopathy (DCM) presenting for heart transplantation and from normal individuals (n=4) using a previously described outgrowth techniques 26, 27 . The protocols used in this study were reviewed and 
Statistical Analysis
GraphPad Prism 6 by GraphPad Software, Inc. was used for statistical analysis. We performed Kolmogorov-Smirnov analysis to test for normality. Additionally, when applicable, we used 1- C CA CA, , cat# S64 4 494 4 4 a a and n n c c con on ontr tr trol ol ol n neg eg egat at ativ iv ive e e #1 #1 #1) ) ) al l lon on ong g g wi i ith h lip p pof of ofec ec ecta ta tami i in n ne R R RNA NA NAiM iM iMAX AX X t t tra ra rans ns nsfe fect ct ctio io ion n n e e eag ag age en e t (cat# # 
Results
Class I and Class II HDAC activities during PO hypertrophy
The HDAC activity was assessed in homogenized tissue from the LV of outbred CD1 male mice 72 hrs, 1 week and 2 weeks post-TAC. As compared to sham mice, Class I HDAC activity increased by 97% and Class II HDAC activity increased by 79% at 1 week post-TAC ( Figure   1A and 1B). Both Class I and Class II HDAC activities remained elevated at 2 weeks post-TAC.
At 72 hrs post-TAC, Class I and II HDAC activities remained unchanged.
Effect of Class I and IIb HDAC inhibition on PO-induced downregulation of miR-133a
The expression of miR-133a was not significantly changed 1week post-TAC and SAHA treatment had no effect on miR-133a levels. miR-133a expression is significantly reduced 2 weeks and 4 weeks post-TAC ( HDACs demonstrates that SAHA treatment effectively inhibited HDAC activity ( Figure 2B ).
The effect of HDAC inhibition on miR-133a's fibrotic targets and cardiac fibrosis
Many profibrotic genes are silenced by miR-133a, including CTGF 7, 28 and Col1a1 6 . Previous studies have shown that the pathological downregulation of miR-133a expression during PO cardiac remodeling allows CTGF and Col1a1 levels to increase, which contributes to collagen synthesis and fibrosis 6, 7 . To test if the restoration of miR-133a expression caused by HDAC inhibition impacts the expression of its profibrotic targets and the development of cardiac fibrosis, we measured CTGF protein levels and examined the extent of cardiac fibrosis with collagen volume fraction in the hearts of TAC mice after 1, 2 weeks and 4 weeks of PO cardiac remodeling. CTGF protein abundance was not significantly changed from control mice after 1 week of PO and HDAC inhibition had no significant effect on CTGF protein levels ( Figure 3A) . e e em mo modeling. CT CT CTGF GF GF pr pr prot ot otei ei ein n n ab a a un un unda da danc nc nce e e wa wa was n n not ot ot sign n nifica a ant nt ntly ly ly c c chang ng nged ed ed f fro ro om m m cont nt ntro ro rol l l mi mi m ce e e a a aft ft f er er er 1 1 1 we w week ek ek of PO and H H HDA AC inhib ib bit t tio i n h had a a no o o sig g gni ifican a ant ef ef ffe fe fec ct o on n n CT T TG G GF pro o ote e ein n n le e evels (F F Fig g gur r re 3 3 3A A A) .
CTGF protein abundance increase e ed d d by by by 75 % af a a te e er r r 2 2 2 we we week ek e s of PO and 61 % after 4 weeks of PO Fi Figu gu g re re 3 3C C). ). ) H HDA DAC C in inhi hibi biti tion on p p pre reve vent nted ed th the e PO PO-d dep ep pen ende dent nt in incr crea ease se i in n CT CTGF GF pr pr p ot otei ein n le leve vels ls 3B and 3C). This represents an increase in interstitial insoluble fibrillar collagen content.
Inhibition of HDAC activity significantly reduced collagen deposition after 2 weeks and 4 weeks of PO when compared to vehicle alone.
The effect of HDAC inhibition on LV structure and function
To determine if the structure and the function of the myocardium were affected by HDAC inhibition, we examined several structural and functional parameters ( TAC as compared to baseline. However, HDAC inhibition had no effect on cardiac hypertrophy (LVW/BW, LVW/TL) and systolic function of the heart (LV EF in Figure 4D and LV EDV in Figure 4E ).
HDAC1 and HDAC2 are associated with miR-133a enhancer regions
miR-133a belongs to the miR-133a/133b family and is associated to the miR-1 family; miR-1-2/133a-1 and miR-1-1/133a-2 originate from bicistronic transcripts on chromosomes 18 and 2 respectively 29 ( Figure 5A ). Enhancers regions have been identified regulating miR-133a-1 and miR-133a-2 expression. On chromosome 2, the intronic region between miR-1-1 and miR-133a-2 stem loops has an intragenic enhancer region regulated by SRF via CArG binding domains 30 , myocardin (MyoD) via E-box domains 17 , and myocyte enhancer factor-2 (MEF2) via the MEF2 box 31 . On chromosome 18, the intronic region between miR-133a-1 and miR-1-2 stem loops also has an intragenic enhancer region regulated by MEF2 and MyoD. Although miR-133a-1 and miR-1-2, and miR-133a-2 and miR-1-1 each share a common enhancer region, miR-133a can be differentially regulated from miR-1 5 . Because there is increased evidence for the role of Class I
HDACs in cardiac pathologies, we performed chromatin immunoprecipitation (ChIP) assay for HDAC1, 2 and 3 on heart tissues from control and 2 weeks TAC mice [32] [33] [34] [35] . Figure 5B shows that HDAC1 and the transcription factor SRF are present on both enhancer regions in all experimental conditions and that HDAC3 is not associated with either enhancer region under any of the conditions. HDAC2 is not present on either enhancer region in the untreated controls but is recruited to the miR-133a-2 enhancer region in the 2-week PO ventricles. Acetylation of histones is positively correlated with increased transcription. Therefore, if miR-133a
transcriptional regulation is mediated primarily by histone acetylation we would predict the enhancer to have less acetylation in PO where miR-133a expression drops. But unexpectedly, histone H3 acetylation is greater in the 2-week post-TAC tissue when compared to control (Supplemental Figure 1) .
Effect of HDAC inhibition on miR-133a expression in cardiac fibroblasts from patients with dilated cardiomyopathy (DCM)
Given the profound effect of HDAC inhibition on fibrotic gene expression in treated murine hearts and the anti-fibrotic profile of miR-133a, we investigated the effect of HDAC inhibition on miR-133a expression in cardiac fibroblasts isolated from DCM and normal patients.
Consistent with our murine data, miR-133a is significantly lower in DCM fibroblasts as compared to normal fibroblasts ( Figure 6A) . Importantly, HDAC inhibition significantly histones is positively correlated with increased transcription. Therefore, if miR-1 1 133 33 33a ranscri ript pt p io i na al re e egu gu g lation is mediated primarily by y y hi h stone acetylation we we we would predict the en en nha ha ancer to ha h h ve ve ve l l less s s ac ac acet et etyl yl ylatio io ion n n in in in P PO O O wh wh wher er ere e e miR R R-133 3a a a ex ex expr pr pres ssi si sion n n d d dro ro ops ps ps. . Bu u ut t t un un unex ex expe pe pect ct cted ed edly ly ly, hi hi histo on one H3 acety y yla a ation n n is s gre e eate te ter in t t the h h 2---week ek ek pos s st--TAC AC AC tis s ssu u ue wh wh when com om ompa a are e ed d to c c con on ontr r rol l l
Supplemental Figure 1).
stimulated miR-133a expression in DCM fibroblasts ( Figure 6C ) but had no effect on miR-133a expression in the normal fibroblasts ( Figure 6B ).
Effect of HDAC2 knockdown on miR-133a expression in DCM fibroblasts.
Since HDAC2 is recruited to the miR-133a-2 enhancer region in the 2-week PO ventricles, we examined the effect of HDAC2 silencing using HDAC2-siRNA in the DCM cells. HDAC2-siRNA knocked down HDAC2 expression in the DCM cells compared to control siRNA ( Figure   7A and 7B). HDAC2 knockdown did not result in the increase of miR-133a expression similar to that observed with HDAC inhibition (control+HDACi). But interestingly, HDAC2
knockdown prevented SAHA stimulated miR-133a expression indicating that although HDAC2
may not be required for miR-133a downregulation in DCM cells, its activity plays a role in the partial restoration of expression seen with HDAC inhibitor treatment.
Discussion
In this study, we examined the epigenetic regulation of miR-133a in the heart during PO-induced cardiac remodeling and fibrosis. We demonstrated 1) Class I and Class II HDAC activities are increased during PO remodeling. 2) Treatment with the Class I and Class IIb HDAC inhibitor SAHA significantly attenuated the PO-induced decrease in miR-133a expression (after 2 and 4 weeks of PO). 3) HDAC inhibition significantly diminished PO-induced upregulation of CTGF protein abundance and collagen deposition, suggesting that the effect of HDAC inhibition on miR-133a expression is reflected on its downstream fibrotic targets. 4) Importantly, the effect of HDAC inhibition on miR-133a expression is also correlated with a reduction in LA diameter and passive stiffness in TAC mice, suggesting improved diastolic function. 5) HDAC1 and HDAC2 knockdown prevented SAHA stimulated miR-133a expression indicating that alth th thou ou ough gh gh H H HDA DA DAC C2 may no not t be be req e ui i ire re r d for miR-133a downregulation n in in DCM cells, its acti ivi vi v ty plays a role in the pa pa part t ti i ial restor rat a a io io on n n of f e e exp xp xpre re ress ss s io o on n n se se seen en en w w wit it ith h h HD HD HDAC A A in nhib bit it itor or or t t tre re r at t tm me ment nt nt. .
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n n t thi his s st stud udy, y, y, w we e ex exam amin ined ed t the he ep ep pig ig gen enet etic ic r reg eg gul ulat atio ion n of of m miR iR-1 133 33a a in in t the he h hea eart rt d dur urin ing g g PO PO-i ind nduc uced ed found in human fibroblast isolated from DCM patients. These data support the hypothesis that acetylation regulates the expression of miR-133a during PO cardiac fibrosis, and it is the first report of the direct association of HDAC1 and HDAC2 with miR-133a promoter by ChIP.
Importance and crosstalk of miRNAs and HDACs
MicroRNAs have been identified as central players in the pathogenesis of various cardiovascular in the LV and atria in multiple murine models of PO-induced cardiac remodeling 4, 5 , is highly expressed in cardiac and skeletal muscle, and is one of the most highly expressed miRNA in cardiomyocytes (although it is also detectable in cardiac fibroblasts). Its expression is decreased as compared to normal in dilated atria from patients with mitral stenosis and in myectomies of ventricles from young patients undergoing curative surgery for hypertrophic cardiomyopathy 4 .
While the biogenesis of miRNAs is well understood, little is known about the regulation of miRNA expression. Interestingly, the miRNA expression profile from heart failure patients is highly similar to the profile of fetally expressed miRNAs 37 Althou ou ough h h t t the in nt nte erpla ay ay b b betwe we een en n e e ep pige e en n netic re egu u ula la lat tor rs a a and d m m miRNA A As s s is s s b b beg e e inn n nin n ng to o be worked out in cancer, very little is is s k k kno no n wn w a abo bo out ut t t thi hi his s co co comp mp mple ex inte t raction in the heart. One recen pa pa pape pe per r r ex ex exam am amin in inin in ing g g th th the e e an an anta ta tago go goni ni nism sm sms s s be be betw tw twee ee een n n IP IP IP 3 39 . Therefore, SAHA treatment would be expected to impact the expression of many other genes in addition to miR133a that contribute in one way or another to PO cardiac remodeling and fibrosis. Identifying these additional targets, which contribute to fibrosis, awaits further evaluation.
HDAC1 and HDAC2 are present on miR-133a enhancer regions
The present study is the first to demonstrate the association of HDAC1 and HDAC2 with the miR-133a-1 and miR-133a-2 enhancer regions. While HDAC1's association with the miR-133a
enhancer regions is similar in the control and pressure overloaded heart, HDAC2 is recruited to the miR-133a-2 enhancer region in the pressure overloaded ventricle. Overexpression of HDAC2 induces hypertrophy 35 . HDAC2 null mice generated by cardiac-conditional knockout remain ufficient for repression of miR-133a expression. Identification of additional co o-o-re e epr r res es esso so sor r r(s (s (s) ) and de ete term rmin nin i g g g th th the role of class I HDACs in the r reg eg gulation of miR-133 3a a a ne n eds further ev ev val l luation. Pr P P ev ev evio io ious s s s s stu tu tudi di dies es e h h hav av ave e e de de demo mo mons n n tr tr trat at ated e e th h hat t clas as ass s s I I I an an a d II II IIb b b HD HD HDAC AC ACs ca a an n n me me medi d d at at ate e e th th the e e ex ex xpr r res e sion of ma a an n ny ot t the e er gen en ne e es s whic ic ch co o ontri i ibu u ute t t to ca ard rd rdia ia iac patho o olo o ogies 39 9 . . T T Th he herefo o ore e e, SA SA SAHA A A reatment would be expected to imp mp mpac a a t the ex x xpr p p es es essi si sion n n o o of f f many y y other genes in addition to miR-susceptible to isoproterenol and PO-induced cardiac hypertrophy 47 , whereas HDAC2 null mice generated by lacZ insertion resist hypertrophic remodeling induced by PO stress 35 . Kee et al. 48 found that induction of HSP70 in response to exogenous hypertrophic stimuli is a key regulatory mechanism to activate HDAC2 in the early phase of cardiac hypertrophy and concluded that HDAC2 is required for hypertrophic responses in the heart.
In order to better understand the role of HDAC2 in miR-133a regulation in an in vitro setting, we utilized siRNA knockdown in the human DCM cells. HDAC2 knockdown did not result in miR-133a upregulation. These data were not completely unexpected. HDAC1 and HDAC2 are recruited by transcription factors either as homo-or heterodimers or as part of multifactor repressor complexes 49 . Although HDAC1 and HDAC2 have some distinctive deacetylase targets 50 , the common theme of many HDAC1/HDAC2 knockdown and knockout studies is redundancy and compensation [51] [52] [53] . In addition HDAC knockdown may exert a completely different effect than inhibiting its catalytic activity 54 . This may be the case for miR133a regulation, HDAC1 may be able to compensate for the loss of HDAC2 but in this case inhibition of HDAC activity did not result in the stimulation of miR-133a expression.
We had expected to find a class I HDAC present after TAC and indeed there is more HDAC2 detected on miR-133a-2 enhancer with TAC than in control hearts. But we anticipated that treatment with SAHA would reduce the presence of HDACs on the enhancer chromatin.
Our finding that HDAC inhibition enhanced the stabilization of HDAC2 with the miR-133a enhancer chromatin in control and TAC mice was unexpected. Importantly, even though more HDAC2 is present on the miR-133a enhancer, SAHA treatment inhibits the deacetylase activity. Both SRF and MEF2 have been shown to undergo acetylation that may affect their activity or interaction with positive or negative cofactors 56, 57 . HOP is one of SRF's co-factor that inhibits SRF transcriptional activity by recruiting a co-repressor complex that includes HDAC2 58 .
Clearly much work remains to identify the exact mechanism by which HDACs regulate miR133a expression in PO cardiac remodeling and fibrosis.
In conclusion, this is the first study focused on the complex interaction between miRNAs and epigenetic regulators in heart disease. Certainly, there is a need to better understand the mechanisms of epigenetic regulation of miRNAs. The potential of HDAC inhibitors and other expression in PO hypertrophy. It is possible that HDAC2 regulates miR-133a ex x xpr pr pre es e si si sion on on b b by y y h the deacet tyl yl y at ation n of f o o or r interaction with transcription fac actors, co-activators or r r co c -repressors on the m m miR R R-133a en n nha ha hanc nc ncer e e . SR SR SRF F F an an and ME ME MEF2 F2 F2 h h hav av ave be be been en en sh h how wn t t to o o pl pl play ay ay a a r r r l ol ole e e in in i c c car ar ardiac ac c e e exp xp xpre re ress s sio io ion n n of of of epigenetic drugs to induce or repress the deregulated miRNAs may provide innovative therapies to reset the epigenome in heart disease. immunoprecipitation (ChIP) to determine whether endogenous Class I HDACs (HDAC1, HDAC2 and HDAC3) as well as SRF are associated with miR-133a enhancer regions (antibodies for HDACs and SRF from Santa Cruz). A negative control, using rabbit IgG as the precipitating antibody, was run to demonstrate the specificity of the ChIP assay. Input DNA from the samples before immunoprecipitation (IP) is also included as a positive control and loading control.
Abbreviations: "veh" for vehicle, and "HDACi" for HDAC inhibitor 
